Well Done John...I am pleased for your profit...I will however hold them for the time being...more positive news flowing and no signs of reversal on the charts...
------------------------------------------
Goldman Sachs has reiterated its “recommended list” stance on Shire Pharmaceuticals (SHP) at £11.10 and is sticking with a £13.50 price target. Schroder Salomon Smith Barney also rates the stock a "buy" with a £16 price target.
------------------------------------------
SHIRE ANNOUNCES POSITIVE OUTCOME IN BIOCHEM PATENT LITIGATION
Andover, UK - 22 December 2000 - Shire Pharmaceuticals Group plc (LSE: SHP.L,
NASDAQ: SHPGY) announces a decision in favour of BioChem Pharma Inc in the
patent dispute between BioChem and Emory University relating to 3TC(R)/Epivir
(R) (lamivudine).
On 11 December 2000, Shire and BioChem announced they had entered into an
agreement to merge the two groups to form a leading global specialty pharma
company. As part of this announcement, information was provided regarding
patent disputes between BioChem and Emory University, relating to US patent
rights for lamivudine. In a decision yesterday, the US Board of Patent Appeals
and Interferences invalidated Emory University's patent relating to
lamivudine. Shire continues to review the detail of the decision but has not
been advised of any intention by Emory to initiate any other action or appeal
the decision.
Rolf Stahel, Chief Executive of Shire, commented 'In evaluating the merger
with BioChem, Shire investigated carefully the patent situation and sought
advice from external counsel on the probability of an adverse ruling. Shire
welcomes the decision of the US Patent Office.'
------------------